Search Result

Results for "

murine osteoarthritis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADAMTS (1) Apoptosis (1) Collagen (2) Exosomes (1)
By Research Areas:	Cardiovascular Disease (1) Inflammation/Immunology (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Targets Recommended: BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P10739

WYRGRL	Exosomes Collagen	Inflammation/Immunology
WYRGRL is a selective, high-affinity collagen type II-binding peptide with a IC₅₀ of 140 nM. Collagen type II is the most abundant and specific structural protein in the extracellular matrix of articular cartilage. WYRGRL can precisely target small-molecule compounds such as Dexamethasone (HY-14648) and nanocarrier-engineered exosomes to cartilage, significantly enhancing their therapeutic effects on osteoarthritis .

HY-P992358

GSK2394002	ADAMTS	Cardiovascular Disease
GSK2394002 is an antibody inhibitor targeting ADAMTS-4 and ADAMTS-5, with cartilage-penetrating ability following systemic administration. GSK2394002 inhibits the release of aggrecan-derived neoepitopes and reduces cartilage degradation, exhibiting the potential to relieve pain, alleviate hyperalgesia and inhibit the progression of joint damage. GSK2394002 also induces potentially irreversible cardiovascular effects such as increased mean arterial pressure and myocardial ischemia in cynomolgus monkeys .

HY-P10739C

WYRGRLC	Collagen Apoptosis	Inflammation/Immunology
WYRGRLC is a type II collagen-targeting peptide. WYRGRLC specifically binds to type II collagen α1 in articular cartilage in a sequence-dependent manner. WYRGRLC inhibits the binding of WYRGRL-displaying phage (C1-3) to articular cartilage in a sequence-specific manner. WYRGRLC can act as a retention enhancer to improve the cartilage-targeting ability of polymeric nanoparticles and liposomal nanoplatforms, facilitating the delivery of Rapamycin (HY-10219) to chondrocytes. WYRGRLC can be used in studies related to osteoarthritis .

Cat. No.	Product Name	Target	Research Area

HY-P10739

WYRGRL	Exosomes Collagen	Inflammation/Immunology
WYRGRL is a selective, high-affinity collagen type II-binding peptide with a IC₅₀ of 140 nM. Collagen type II is the most abundant and specific structural protein in the extracellular matrix of articular cartilage. WYRGRL can precisely target small-molecule compounds such as Dexamethasone (HY-14648) and nanocarrier-engineered exosomes to cartilage, significantly enhancing their therapeutic effects on osteoarthritis .

HY-P10739C

WYRGRLC	Collagen Apoptosis	Inflammation/Immunology
WYRGRLC is a type II collagen-targeting peptide. WYRGRLC specifically binds to type II collagen α1 in articular cartilage in a sequence-dependent manner. WYRGRLC inhibits the binding of WYRGRL-displaying phage (C1-3) to articular cartilage in a sequence-specific manner. WYRGRLC can act as a retention enhancer to improve the cartilage-targeting ability of polymeric nanoparticles and liposomal nanoplatforms, facilitating the delivery of Rapamycin (HY-10219) to chondrocytes. WYRGRLC can be used in studies related to osteoarthritis .

Cat. No.	Product Name	Target	Research Area	Image

HY-P992358

GSK2394002	ADAMTS	Cardiovascular Disease
GSK2394002 is an antibody inhibitor targeting ADAMTS-4 and ADAMTS-5, with cartilage-penetrating ability following systemic administration. GSK2394002 inhibits the release of aggrecan-derived neoepitopes and reduces cartilage degradation, exhibiting the potential to relieve pain, alleviate hyperalgesia and inhibit the progression of joint damage. GSK2394002 also induces potentially irreversible cardiovascular effects such as increased mean arterial pressure and myocardial ischemia in cynomolgus monkeys .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.